An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02726581.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationBristol-Myers Squibb

• Primary IDCA209-602
• Secondary IDsNCI-2016-00875, 2015-005699-21
• ClinicalTrials.gov IDNCT02726581